| 摘要 |
<p>Medicaments contain, in addn. to the usual additives, (A) ursodeoxycholic acid (I) and a phenoxy-isobutyric acid deriv. B-C6H4-O-C(Me)2-CO-O-A (II) or, when (II) is N-contg., a salt thereof with an acid (where A is H, 1-6C alkyl, omega-hydroxy-(1-4C alkyl) (opt. esterified with a 4-substd. benzoic acid or with nicotinic acid),on alkali (ne earth) cation, 7-12C aralkyl, nicotinyl, or a piperidyl group (opt. N-alkyl substd.); and B is H, halo, 1-6C alkyl (the terminal C-atom of which is opt. coupled with a benzoic acid deriv.), 7-12C aralkyl, aryl (opt. substd. by halo, or 1-6C alkyl), or opt. fully or partially hydrogenated cyclic aryl gps.). Used as hypolipaemic agents for use in e.g. the prophylaxis of coronary heart disease. Ursodeoxycholic acid prevents the tendency to cholelithiasis attributable to the hypolipaemic agent (II) (the lithogenic index being lower even than the initial value before administration of (II)) without aversely affecting (indeed enhancing) the hypolipaemic action of (II). Ursodeoxycholic acid is free from the toxic side-effects of chenodeoxycholic acid.</p> |
